Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 32 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

9%

3 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

N/A
21(84.0%)
Phase 4
2(8.0%)
Early Phase 1
1(4.0%)
Phase 3
1(4.0%)
25Total
N/A(21)
Phase 4(2)
Early Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (32)

Showing 20 of 32 trials
NCT07523490Recruiting

Investigation on Suicide Risk Factors of Patients With Mood Disorders

Role: lead

NCT07448675Enrolling By Invitation

Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness

Role: lead

NCT06524505Not ApplicableRecruiting

Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression

Role: lead

NCT07393464Not ApplicableNot Yet Recruiting

PQQ for Cognitive and Negative Symptoms

Role: lead

NCT07356765Not ApplicableEnrolling By Invitation

Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms

Role: lead

NCT07359209Not ApplicableEnrolling By Invitation

Berberine Improving Cognitive Impairments in Schizophrenia

Role: lead

NCT07162467Enrolling By Invitation

Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.

Role: lead

NCT06692361Not ApplicableRecruiting

Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder

Role: collaborator

NCT07139171Recruiting

Study on the Role and Mechanism of Plasma Exosome microRNAs in Cognitive Impairment in First-episode Schizophrenia

Role: lead

NCT07102069Completed

Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia

Role: lead

NCT07031544Not ApplicableRecruiting

Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder

Role: collaborator

NCT06477276Not ApplicableCompleted

Amygdala TIS for Depression

Role: collaborator

NCT06812923Not ApplicableRecruiting

TACS on High-inflammatory and Refractory Depression

Role: lead

NCT06172413Not ApplicableUnknown

Transcranial Alternating Current Stimulation for Treatment-Resistant Depression

Role: collaborator

NCT04853485Not ApplicableUnknown

Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes

Role: collaborator

NCT03932136Phase 3Recruiting

Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

Role: collaborator

NCT03548155Not ApplicableCompleted

Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia

Role: lead

NCT05915312Unknown

Exosome for Early Diagnosis of Bipolar Affective Disorder

Role: lead

NCT05695144Not ApplicableUnknown

tDCS Combined With rTMS for Negative Symptoms of Schizophrenia

Role: lead

NCT05646264Phase 4Unknown

A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia

Role: collaborator